Member Info for Brighty1

LGEN should take a look at buying JUST Group. Excellent numbers from Just today with profit up 154% to £173m (H1 22: £68m)

Plus, retirement Income sales more than double to £1.9bn (H1 22: £0.9bn)

Just also reporting a 112% increase in new business profits to £161m (H1 22: £76m), with a "consistently strong new business margin of 8.5% (H1 22: 8.6%)"

Both the DB and retail markets remain buoyant, with a record pipeline of DB business.

Net assets per share of 204p.

Other key messaging:

* Adjusted profit before tax was £246m (H1 22: adjusted loss before tax £185m), driven by strong growth in underlying operating profit, and investment and economic profits. Of this £246m, £129m of profit is deferred to CSM4 in the balance sheet, leaving an IFRS profit before tax of £117m (H1 22: IFRS loss before tax of £237m).

* Improved return on equity to annualised 13.0% and tangible net assets per share of 204p (H1 22: 5.4% and 31 December 2022: 190p respectively).

JUST would be a great buy for LGEN...

Good luck, Brighty

Yes, we should hit 15p very soon on this TESCO news. A fantastic day for ABDX. It's also worth pointing out that this share can fly on news. Just look what happened in the seven day period from 17th August'21 to 24th August'21 ABDX went from 26.50p to 85.50p. i.e. A x 3 increase within 7 days. It's also safe to say that the UK's first ever saliva-based pregnancy test is a game changer for ABDX. The market is massive for home pregnancy testing: 12.5 million tests in the UK alone each year. The really exciting point is that Salistick is just one of many tests ABDX is bringing to market....

Good luck, Brighty

L&G should / could put a bid in for JUST. There was an article about a 200p takeover price for JUST in Investors Chronicle a few months ago. A takeover is what I'm expecting and probably north of 200p a share based on these numbers. Surely JUST will hit 100P a share again soon before moving upwards for a 200p+ a share takeover. Don't forget also that Quliter went up 12% on good results last week....Good luck, Brighty

Tesco to roll-out Salistick from end of this month

* The launch of Salistick will be focused on larger Tesco stores as well as online at Tesco.com.

* This follows the initial launch of Salistick with Superdrug in 400 stores and online at Superdrug.com.

* Launching a Salistick dual pack in due course.

Excellent news.

Good luck, Brighty

Brilliant numbers from Just today with profit up 154% to £173m (H1 22: £68m)

Plus, retirement Income sales more than double to £1.9bn (H1 22: £0.9bn)

Just also reporting a 112% increase in new business profits to £161m (H1 22: £76m), with a "consistently strong new business margin of 8.5% (H1 22: 8.6%)"

Both the DB and retail markets remain buoyant, with a record pipeline of DB business.

Net assets per share of 204p.

Other key messaging:

* Adjusted profit before tax was £246m (H1 22: adjusted loss before tax £185m), driven by strong growth in underlying operating profit, and investment and economic profits. Of this £246m, £129m of profit is deferred to CSM4 in the balance sheet, leaving an IFRS profit before tax of £117m (H1 22: IFRS loss before tax of £237m).

* Improved return on equity to annualised 13.0% and tangible net assets per share of 204p (H1 22: 5.4% and 31 December 2022: 190p respectively).

This is even better than expected.

Good luck, Brighty

Significant news today from MGC in relation to the pre-clinical toxicology evaluation of CimetrA delivering positive results

* Study demonstrated full chronic safety and toxicology profile of CimetrA® in large animals was found to be totally safe.

* Supports previous pre-clinical and clinical data.

* An important step in the IND submission preparation for the US Food and Drug Administration.

The full briefing is at: https://www.londonstockexchange.com/news-article/MXC/positive-pre-clinical-trial-results-on-cimetra-r/16081373

Excellent news...

Good luck, Brighty

If it is the same John Robert Barker he has been involved with MOS since April (according to his profile) and he now holds 5.03%. That's an interesting observation you make by the way regarding his timing of buying more shares now....

See the Linked In profile and scroll down.

https://uk.linkedin.com/in/jbarker2402?original_referer=https%3A%2F%2Fwww.google.com%2F

Good luck, Brighty

One very likely scenario being overlooked here is that a major pharma player licences the Genedrive MT-RNR1 ID Kit. A multi million licencing deal would enable GDR to have serious money to focus on the stroke test. e.g. In the pharma sector there were 479 M&A deals announced in Q2 2023, worth a total value of $51 Billion (according to GlobalData's Deals Database). You only have peruse the JP Morgan research note regarding the high levels of R&D licencing deals in the pharma sector to see that this could be a very likely outcome here. A takeover is also possible. Some of the recent smaller deals include Shionogi announcing on June 26th its plans to acquire Qpex Bio for $100 million upfront, with potential for additional payments and on June 29 Eli Lilly announced it planned to acquire Sigilon, a small bio for $34.6 million. Sigilon’s stock jumped over 600%.

In summary, dont rule out either a monster licencing deal for the MT-RNR1 ID Kit or a takeover. GDR's MT-RNR1 is the first of its kind in the world and big pharma won't want to miss out. It's all to play for here especially as our chairman has a track record of multi million deals for his previous companies....

Good luck, Brighty

Some positive data just out: "UK GDP was up by 0.2% in the second quarter of the year, defying expectations of stagnation. The economy grew by a stronger-than-expected 0.5% in June as good weather boosted many sectors".

Good luck, Brighty

Guys, calm down! You do know that funding from Health Innovation Manchester is supporting the roll out? See Jonathan Massey's quotes below. Plus the rumour mill is working overdrive on Devote being the main funder for the GDR MT-RNR1 ID Kit. The company just needs to get its RNS / PR briefing machine out as GDR will not be paying for all of this. Background below:

* Jonathan Massey, Programme Director for Academia at Health Innovation Manchester said: “Health Innovation Manchester funding is supporting the wider adoption across the city-region, ensuring that the work done to date will translate to better and equitable patient outcomes, wherever a child is treated in Greater Manchester.”

* Vulnerable newborns at Manchester hospital first to benefit from rollout of genetic test to prevent hearing loss

* An innovative genetic test that can help prevent newborn babies from going deaf if treated with a common antibiotic, is now being used in routine clinical practice in maternity settings at Manchester University NHS Foundation Trust (MFT).

* Using a simple cheek swab, the test can identify in 26 minutes whether a critically ill baby admitted to intensive care has a gene change that could result in permanent hearing loss if they are treated with a common emergency antibiotic, Gentamicin. The rapid point of care test, developed by researchers from MFT, working with Manchester company genedrive plc, was first piloted at Saint Mary’s Hospital and Liverpool Women’s Hospital in 2021.

* Following its success, the test was implemented into routine clinical practice at Saint Mary’s Hospital in 2022, which has now been extended to North Manchester General Hospital (NMGH) and Wythenshawe Hospital, part of Saint Mary’s Managed Clinical Service at MFT in July 2023.

* It is estimated that approximately 1,700 babies a year will be tested at MFT, which has so far prevented the hearing loss of six babies in Greater Manchester since the pilot in 2021 through to the implementation of the test in 2022.

Good luck, Brighty

40p coming soon. TLW will get back to £1+ a share in due course...

Good luck, Brighty

Latino, you are probably right that GFIN will now go on a run - maybe as much as x 4 or x 5 - from here at some stage. It looks like from the 750 Million shares placed 400 Million approx have been taken up by directors so taking it private / mbo is still what I think is going on here. That still makes this very interesting. However, I just don't like the fact that on 6th June they said there was no funding required to then raise 2 months later....

Good luck, Brighty

Outrageous. On June 6th Chairman, Neville Upton commented " after a significant re-structuring, we are confident that Gfinity will flourish without the requirement to raise further working capital".... Well that was short lived ....

Brighty

This gets more interesting every day there is no speeding ticket as the word must be out in some quarters that something is brewing here. John Story and Robert Keith (RK best known for Eidos /Lara Croft) hold approx 29.3% of GFIN. A x 4/5 or even x 10 rise on the right kind of news is possible....

Good luck, Brighty

In answer to your question the exercise price of the initial warrants payable to GDR are exercisable at 44.8p a share, plus that warrants are exercisable for up to four years. i.e. RF will want the share price to be at least 44.8p in due course and are probably expecting it to be much higher and won't necessarily sell at 44.8p either. We also know that revenue is starting to be created with the tests so subject to numbers / our next update we could be way over 50p a share. I expect this to be in the hundreds of pence in the future. DYOR.....

Good luck, Brighty

Up 56% now and no speeding ticket....

Good luck, Brighty

Yes, nice one Jimi. All coming together nicely. Some great background and quotes, a few pasted below for those that haven't read the link, including about rolling it out across ALL maternity services in England. Would be great for an update from GDR soon....

* "Our ambition is to see this test rolled out across all maternity services in England so that all babies and families can benefit from this test"

* "While MFT is the first trust to routinely use the test, other NHS trusts in Greater Manchester will soon follow. Bolton NHS Foundation Trust​, Northern Care Alliance NHS Foundation Trust, Tameside and Glossop Integrated Care NHS Foundation Trust​ and Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust are also set to introduce the revolutionary test in 2023"

* Manchester-based firm genedrive plc developed the genetic based test with researchers based at MFT, supported by the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC) and The University of Manchester.

David Budd, CEO, genedrive, said: “The continued rollout of the Genedrive® MT-RNR1 test demonstrates the engagement with new technology by the MFT clinical teams as well as the positive health impact that point of care molecular testing can have on patients. By having their genetic susceptibility to aminoglycoside treatment rapidly and easily checked prior to treatment, the expanded availability of the Genedrive® MT-RNR1 test throughout the North West region will provide every newborn access to safer and more assured treatment.”

Good luck, Brighty

42% up now. The herd are still to arrive. This could go up significantly...

Good luck, Brighty

Quilter up over 12% today on good interim numbers announced today. Hopefully we can have a repeat here...

Good luck, Brighty

32% up today. I do wonder if an MBO or bid at a bargain basement price is being planned? Between them it would appear that John Story and Robert Keith hold approx 29.3% of GFIN. Robert Keith, for those that don’t know is a serious player. He is the hi-tech investor best known for Eidos (Lara Croft) and holds 318,477,778 shares in GFIN (12.02%). This could go x 4/5 or even x 10 on the right kind of news. Looks like something could be brewing here at last. One to watch....

Good luck, Brighty